biostudies-literatureUnknown177Silecchia GEthicon Endo-Surgery IncJohnson and Johnson<h4>Background</h4>Sars-Cov-2 epidemic in Italy caused one of the greatest 2020 European outbreaks, with suspension of elective bariatric/metabolic surgery (BMS). From May 2020 a significant decline of the epidemic has been observed (phase 2); National Health Service protocols permitted elective BMS' resumption. A new, more severe COVID-19 surge, the "second wave", started on October 2020 (phase 3).<h4>Aim</h4>The primary end point was to analyze the outcomes of any Sars-Cov-2 infection and related morbidity/mortality within 30 POD after laparoscopic BMS during phase 2-3; secondary end points were readmission and reoperation rates.<h4>Methods</h4>Study design prospective, multicenter, observational.<h4>Setting</h4>Eight Italian high-volume bariatric centers. All patients undergoing BMS froDiabetes research and clinical practice108919https://www.ebi.ac.uk/biostudies/studies/S-EPMC8200253biostudies-literatureLaparoscopic bariatric surgery is safe during phase 2-3 of COVID-19 pandemic in Italy: A multicenter, prospective, observational study.PMC8200253Bernante PSilecchia GAnselmino MBianciardi ECampanelli MM Marinari GFiorello LMancini RBoru CETascini CMorino MFoletto MTrotta MOldani ASalzano ARottoli Mcooperative RESTART groupMorganti RGentileschi POlmi SfalseLaparoscopic bariatric surgery is safe during phase 2-3 of COVID-19 pandemic in Italy: A multicenter, prospective, observational study.<h4>Background</h4>Sars-Cov-2 epidemic in Italy caused one of the greatest 2020 European outbreaks, with suspension of elective bariatric/metabolic surgery (BMS). From May 2020 a significant decline of the epidemic has been observed (phase 2); National Health Service protocols permitted elective BMS' resumption. A new, more severe COVID-19 surge, the "second wave", started on October 2020 (phase 3).<h4>Aim</h4>The primary end point was to analyze the outcomes of any Sars-Cov-2 infection and related morbidity/mortality within 30 POD after laparoscopic BMS during phase 2-3; secondary end points were readmission and reoperation rates.<h4>Methods</h4>Study design prospective, multicenter, observational.<h4>Setting</h4>Eight Italian high-volume bariatric centers. All patients undergoing BMS fro2021-01-01T00:00:00Z2021 Jul2025-04-04T10:49:32.195Z2022-02-11T02:16:38.09ZS-EPMC82002533413396210.1016/j.diabres.2021.108919